Prolonged continuous infusion of low-dose rIL-2.

Por Janssen, R. A., Buter, J., The, T. H., Mulder, N. H., de Leij, L.
Publicado em 1994

Immunomodulatory effects of intravenous BIS-1 F(ab')2 administration in renal cell cancer patients.

Por Janssen, R. A., Kroesen, B. J., Buter, J., Mesander, G., Sleijfer, D. T., The, T. H., Mulder, N. H., de Leij, L.
Publicado em 1995

Phase I study of intravenously applied bispecific antibody in renal cell cancer patients receiving subcutaneous interleukin 2.

Por Kroesen, B. J., Buter, J., Sleijfer, D. T., Janssen, R. A., van der Graaf, W. T., The, T. H., de Leij, L., Mulder, N. H.
Publicado em 1994

Salvage surgery in post-chemoradiation laryngeal and hypopharyngeal carcinoma: outcome and review

Por PUTTEN, L., BREE, R., DOORNAERT, P.A., BUTER, J., EERENSTEIN, S.E.J., RIETVELD, D.H.F., KUIK, D.J., LEEMANS, C.R.
Publicado no Acta Otorhinolaryngol Ital (2015)

GE-10 IDENTIFICATION OF PATIENTS WITH RECURRENT GBM THAT BENEFIT FROM BEVACIZUMAB

Por Eraslan, Lale Erdem, van den Bent, Martin, Kros, Johan, Oosterkamp, Hendrika, Walenkamp, Annemiek, Beerepoot, Laurens, Hanse, Monique, Buter, J., Honkoop, Aafke, van der Holt, Bronno, Vernhout, R.M., Smitt, Peter Sillevis, Taal, Walter, French, Pim
Publicado em 2014

Prognostic value of the S100B protein in newly diagnosed and recurrent glioma patients: a serial analysis

Por Holla, F. K., Postma, T. J., Blankenstein, M. A., van Mierlo, T. J. M., Vos, M. J., Sizoo, E. M., de Groot, M., Uitdehaag, B. M. J., Buter, J., Klein, M., Reijneveld, J. C., Heimans, J. J.
Publicado no J Neurooncol (2016)

Phase I dose-escalation study to determine the safety, pharmacokinetics and pharmacodynamics of brivanib alaninate in combination with full-dose cetuximab in patients with advanced...

Por Garrett, C R, Siu, L L, El-Khoueiry, A, Buter, J, Rocha-Lima, C M, Marshall, J, LoRusso, P, Major, P, Chemidlin, J, Mokliatchouk, O, Velasquez, L, Hayes, W, Feltquate, D, Syed, S, Ford, S, Kollia, G, Galbraith, S, Nuyten, D S A
Publicado em 2011

IDENTIFICATION OF PATIENTS WITH RECURRENT GBM THAT BENEFIT FROM BEVACIZUMAB

Por French, Pim, Erdem-Eraslan, L., Kros, J.M., Oosterkamp, H.M., Walenkamp, A.M.E., Beerepoot, L., Hanse, M., Buter, J., Honkoop, A., van der Holt, B., Vernhout, R.M., Sillevis Smitt, P.A.E., Taal, W., van den Bent, M.J.
Publicado em 2014

O10.05 FINAL ANALYSIS OF THE BELOB TRIAL (A RANDOMIZED PHASE II STUDY ON BEVACIZUMAB VERSUS BEVACIZUMAB PLUS LOMUSTINE VERSUS LOMUSTINE SINGLE AGENT IN RECURRENT GLIOBLASTOMA) AND...

Por Taal, W., Oosterkamp, H.M., Walenkamp, A.M.E., Dubbink, H.J., Beerepoot, L.V., Hanse, M., Buter, J., Honkoop, A., Boerman, D., Vos, F.Y.F., Dinjens, W.N.M., Enting, R.H., Taphoorn, M.J.B., van den Berkmortel, F.W.P.J., Jansen, R., Brandsma, D., Bromberg, J.E., van Heuvel, I., Vernhout, R.M., van der Holt, B., van den Bent, M.J.
Publicado em 2014